A Phase I Dose Escalation Study Of TGR-1202, a Novel PI3K-δ Inhibitor, For Patients With Relapsed Or Refractory Hematologic Malignancies
Savona M, Gutierrez M, Lanasa M, et al.
Key Points:
TGR-1202 new Akt phosphorylation inhibitor which can induce apoptosis in lymphoma and leukemia cell lines.
Phase I, open label study of the oral PI3K-δ inhibitor, TGR-1202.
Patients with ECOG PS ≤2 and B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), peripheral T-cell lymphoma, or other lymphoproliferative disorders previously received at least one prior treatment eligible.
No G3/4 related hematologic or non-hematologic toxicities observed.
Implications:
TGR-1202 well tolerated in patients with relapsed/refractory hematologic malignancies.
No DLTs observed and toxicities have been minimal to date.
View the original abstract on the ASH website.
